



# Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease

Katie J. Bayfield <sup>1,9</sup>, Oliver Weinheimer <sup>2,3,9</sup>, Christie Boyton <sup>1</sup>, Rachel Fitzpatrick <sup>1</sup>, Anna Middleton <sup>1</sup>, Brendan Kennedy <sup>1</sup>, Anneliese Blaxland <sup>1</sup>, Geshani Jayasuriya <sup>1,4</sup>, Neil Caplain <sup>1</sup>, Hana Issa <sup>1</sup>, Robert Goetti <sup>1</sup>, Mark O. Wielpütz <sup>1,2,3</sup>, Lifeng Yu <sup>5</sup>, Craig J. Galban <sup>6</sup>, Terry E. Robinson <sup>7</sup>, Brian Bartholmai <sup>5</sup>, Dominic Fitzgerald <sup>1,8</sup>, Hiran Selvadurai <sup>1,8</sup> and Paul D. Robinson <sup>1,4,8</sup>

<sup>1</sup>The Children's Hospital at Westmead, Westmead, Australia. <sup>2</sup>Department of Diagnostic and Interventional Radiology, University Hospital of Heidelberg, Heidelberg, Germany. <sup>3</sup>Translational Lung Research Center Heidelberg, German Center for Lung Research DZL, Heidelberg, Germany. <sup>4</sup>Woolcock Institute of Medical Research, Sydney, Australia. <sup>5</sup>Division of Radiology, Mayo Clinic Rochester, Rochester, MN, USA. <sup>6</sup>Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA. <sup>7</sup>Stanford University Medical Centre, Stanford University, Stanford, CA, USA. <sup>8</sup>The University of Sydney, Sydney, Australia. <sup>9</sup>Joint first authors.

Corresponding author: Paul D. Robinson ([paul.robinson@uq.edu.au](mailto:paul.robinson@uq.edu.au))



Shareable abstract (@ERSpublications)

**Early cystic fibrosis lung disease requires urgent sensitive outcome measures. Ultra-low dose CT provides comparable quantitative structural insight into bronchiectasis compared to conventional low dose CT, but higher rates of air trapping.** <https://bit.ly/3Wi8MLr>

**Cite this article as:** Bayfield KJ, Weinheimer O, Boyton C, *et al.* Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease. *Eur Respir J* 2023; 62: 2300286 [DOI: 10.1183/13993003.00286-2023].

This single-page version can be shared freely online.

Copyright ©The authors 2023.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 31 March 2021  
Accepted: 10 May 2023

*To the Editor:*

Optimal characterisation of early structural abnormalities has been highlighted as critical to future efforts to detect and prevent cystic fibrosis (CF) lung disease progression [1]. Computed tomography (CT) is currently the gold standard, detecting structural disease at an earlier stage than radiography or lung function testing, with predictive value for subsequent progression and later forced expiratory volume in 1 s (FEV<sub>1</sub>) decline [1]. Compared to other emerging radiological modalities for early disease detection, such as magnetic resonance imaging (MRI), CT is more widely accessible and MRI at present is not able to directly quantify the extent of bronchiectasis due to its limitations in spatial resolution. Current US CF Foundation clinical guidelines state that CT should be “considered every 2–3 years, using the lowest possible radiation dose” [2]. Early lung disease is identified on CT by air trapping, increase in airway wall thickness and airway diameter, and potentially irreversible bronchiectasis [3]. Spirometer-directed CT has standardised lung volume acquisition and outlined the importance of both inspiratory and expiratory image acquisition [4]. Consensus recommendations for “low dose” CT scanning were published in 2016 [5], but radiation exposure remains a concern, given the six-fold increase in CT use and ongoing increase in cumulative radiation exposure for CF patients [6]. Imaging requires optimal structural information at the lowest possible radiation dose [5]. Given the increased vulnerability of children to ionising radiation, “low dose” CT protocols have already been incorporated in paediatric clinical trials using CT-based primary outcome measures [7], and use of ultra-low dose (ULD) CT has emerged in adult CF research and in isolated paediatric patients [6]. However, formal validation of the effects on quantitative measures of structural disease has not been performed. Low dose (LD) CT shows limitations compared to standard dose CT because of known drifts in CT lung density dependent on dose [8]. We hypothesised that ULD implementation would not detrimentally affect structural disease detection in early CF lung disease, and specifically targeted an age range to explore this where volume variation during spirometry-directed CT could be minimised between imaging modalities. Thus, the primary aims in this study were to 1) implement spirometer-directed novel ULD CT in school-aged children with CF, and 2) validate its



outcomes against same-session LD CT using visual as well as fully automated quantitative CT analysis for structural airway disease.